The U.S. Food and Drug Administration (FDA) issued a drug safety warning for Kayexalate (sodium polystyrene sulfonate), as the potassium-lowering drug may decrease the effectiveness of other oral medications by binding to them. The FDA is requiring the manufacturer of Kayexalate to conduct studies to evaluate this reaction.

According to the Agency, health care providers prescribing the drug should "consider separating Kayexalate dosing from other orally administered medications by at least six hours."

Read the FDA’s Drug Safety Communication.

Keywords: Administration, Oral, Pharmaceutical Preparations, Polystyrenes, Potassium, United States Food and Drug Administration

< Back to Listings